Belgium· BE-AMP-SAM665981-00
Enflonsia 105 mg
A clesrovimab product containing clesrovimab, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Clesrovimab is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BD10 (clesrovimab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Clesrovimab · ATC J06BD10
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Clesrovimab
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- J06BD10
- ATC class
- Clesrovimab
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Clesrovimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaENFLONSIAMerck Sharp & Dohme B.V., Haarlem
- SpainENFLONSIA 105 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAMerck Sharp & Dohme B.V.
- IcelandEnflonsiaMerck Sharp & Dohme B.V.*
- NorwayEnflonsiaMerck Sharp & Dohme B.V.
- PolandEnflonsiaMerck Sharp & Dohme B.V.
- SwedenEnflonsia 105 mg Injektionsvätska, lösning i förfylld sprutaMerck Sharp & Dohme BV
- SwitzerlandEnflonsia
- FinlandEnflonsiaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enflonsia
- Liechtenstein · Enflonsia
- Norway · Enflonsia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5378a6ea-8ad4-47eb-af28-2d677e75f5db GET /v1/drugs/5378a6ea-8ad4-47eb-af28-2d677e75f5db?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Enflonsia 105 mg",
"name_fr": "Enflonsia 105 mg",
"name_nl": "Enflonsia 105 mg",
"amp_code": "SAM665981-00",
"strengths": [
"105.0000",
"105.0000",
"0.1400"
],
"pack_count": 7,
"substances": [
"Clesrovimab",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Clesrovimab",
"authorisation_numbers": [
"EU/1/25/1984/001",
"EU/1/25/1984/006",
"EU/1/25/1984/007",
"EU/1/25/1984/004",
"EU/1/25/1984/003",
"EU/1/25/1984/005",
"EU/1/25/1984/002"
]
}See everything about clesrovimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.